Iovance Biotherp Stock Price, News & Analysis

On May 6, 2021, Iovance Biotherapeutics (NASDAQ: IOVA) released its Q1 2021 financial results, highlighting significant progress in its TIL therapies for various cancers. The company reported a net loss of $75.4 million or $0.51 per share, with cash reserves of $610.2 million as of March 31, 2021, sufficient to fund operations into 2023. The ongoing clinical trials for lifileucel in melanoma and cervical cancer show promising response rates, including a 36.4% overall response rate in advanced melanoma. Iovance also announced an updated license agreement with NIH, enhancing its patent portfolio.

Iovance Biotherapeutics (NASDAQ: IOVA) announced participation in several virtual conferences in May 2021, focusing on their T cell-based cancer immunotherapies. Key presentations include a fireside chat at the Truist Securities Life Sciences Summit on May 5, a talk on tumor infiltrating lymphocytes (TILs) at the Multi-Functional Cell Therapies Summit on May 6, a presentation at the PEGS Boston Virtual Conference on May 13, and a keynote at the Sachs Associates Immuno-Oncology Forum on May 19. Iovance aims to enhance treatment for solid tumors and blood cancers using TIL therapy.

Iovance Biotherapeutics has announced key findings from clinical trials for its T cell-based therapy lifileucel at the ASCO 2021 Annual Meeting. The presentations will focus on lifileucel's efficacy for advanced melanoma, both as a standalone treatment and in combination with pembrolizumab. Two abstracts have been accepted: one evaluating the impact of prior anti-PD-1 therapy and the other assessing the safety and efficacy of the combination therapy for patients who have not previously received immune checkpoint inhibitors. The meeting is scheduled for June 4-8, 2021.

Iovance Biotherapeutics will report its first quarter financial results on May 6, 2021, at 4:30 PM ET, followed by a conference call. The company specializes in T cell-based cancer immunotherapies, particularly tumor infiltrating lymphocyte (TIL) therapy, targeting solid tumors and blood cancers. Iovance has completed dosing in pivotal programs for metastatic melanoma and cervical cancer, and is conducting studies for non-small cell lung cancer and earlier stage cancers. Details of the conference call can be found on their website.

Iovance Biotherapeutics (NASDAQ: IOVA) announced promising results from Cohort 2 of the C-144-01 study of lifileucel, a T cell-based therapy for advanced melanoma.

Key findings include a median duration of response not reached at 28.1 months and a 36.4% overall response rate, with 17% of patients showing deepening responses. These results demonstrate the therapy's durability in challenging cases of metastatic melanoma. The data will be presented at the AACR 2021 Annual Meeting, highlighting the potential of lifileucel for future trials in solid tumors.

Iovance Biotherapeutics has appointed Igor Bilinsky, Ph.D., as Chief Operating Officer, effective immediately. Dr. Bilinsky brings over 20 years of experience in biotechnology, including senior roles at Oncternal Therapeutics and AmpliPhi Biosciences. His expertise in operational leadership and manufacturing is expected to enhance Iovance’s TIL cell therapy pipeline and potential commercialization. Iovance focuses on T cell-based therapies for cancer treatment, including pivotal studies in melanoma and cervical cancer.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced that long-term interim data from Cohort 2 of the C-144-01 clinical study in advanced melanoma will be presented at the AACR 2021 Annual Meeting. The presentation will focus on the efficacy of Lifileucel (LN-144), a T cell-based therapy, showing durable responses at 28-month follow-up. In addition to this oral presentation, three poster presentations will elaborate on ongoing clinical trials in solid tumors and chronic lymphocytic leukemia. The AACR meeting takes place virtually on April 10, 2021.

Iovance Biotherapeutics has announced upcoming presentations at various virtual healthcare conferences. Key events include the Cowen 41st Annual Health Care Conference on March 3 at 1:20 p.m. ET, H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. ET, Barclays Global Healthcare Conference on March 11 at 1:50 p.m. ET, and Oppenheimer 31st Annual Healthcare Conference on March 17 at 1:10 p.m. ET. The webcasts of these presentations will be available on the Iovance website.

Iovance Biotherapeutics (NASDAQ: IOVA) reported its Q4 and full-year 2020 financial results, showing a cash position of $635 million, expected to last into 2023. The company emphasized progress in its TIL cell therapies across various cancers, including melanoma and cervical cancer, and plans for a potential BLA submission in 2021. R&D expenses rose to $201.7 million for the year, while general and administrative expenses increased to $60.2 million. The net loss for Q4 was $68.4 million, with a full-year net loss of $259.6 million.